Status:
COMPLETED
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
Lead Sponsor:
Hedvig Marie Egeland Nordeng
Conditions:
Hyperemesis Gravidarum
Emesis
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Nausea and vomiting in pregnancy (NVP) is affecting up to 70% of pregnant women. Studies have also shown that NVP may have a profound impact on pregnant women's wellbeing and that even mild NVP sympto...
Detailed Description
Nausea and vomiting in pregnancy (NVP) is one of the most common pregnancy-related ailments, affecting up to 70% of pregnant women. The causes of NVP are unclear but it has been described as multifact...
Eligibility Criteria
Inclusion
- Pregnant women currently experiencing all degrees of NVP
- Owners of a smartphone (iOS or Android) with phone lock
- Speak and understand Norwegian
Exclusion
- \-
Key Trial Info
Start Date :
September 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 16 2022
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT04719286
Start Date
September 2 2019
End Date
May 16 2022
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pharmacy, University of Oslo
Oslo, Norway, 0371